You are here: Industry Insights > Market News > Doctors Accuse NextSource Biotech for Hiking the Price on Key Cancer Drug Nine Times

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Doctors Accuse NextSource Biotech for Hiking the Price on Key Cancer Drug Nine Times

biospaceDecember 29, 2017

Tag: drug prices , NextSource

Favorites

The cost of a vital cancer drug has gone up 15-fold in four years after its new owner hiked prices on nine separate occasions.

Lomustine has been used to treat brain tumours, lung cancer and Hodgkin’s lymphoma for more than 40 years but is now seen by some patients as too expensive.

In 2013, production of the drug, which was previously called CeeNU, passed from pharma giant Bristol-Myers Squibb to a Miami-based startup called NextSource Biotechnology.

Previous:Todd Campbell notes four biopharma stocks that topped out in the S&P 5

Next:Amneal Pharmaceuticals welcomes new President Robert Stewart

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Doctors Accuse NextSource Biotech for Hiking the Price on Key Cancer Drug Nine Times | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Doctors Accuse NextSource Biotech for Hiking the Price on Key Cancer Drug Nine Times

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Doctors Accuse NextSource Biotech for Hiking the Price on Key Cancer Drug Nine Times

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>